Hot Investor Mandate 4: Transatlantic Fund Invests In Early Stage Therapeutics and Diagnostics for Chronic Diseases

2 Jun

A transatlantic healthcare technology focused on seed-stage funding sources opportunities from global institutions, leading technology incubators and its deep healthcare network. The firm typically leads investments as the first money into projects spun out of these entities. The firm focuses on companies based in the U.S. and the UK.

In the Life Sciences space, the firm is currently seeking new investments in therapeutics, diagnostics, and digital health targeting chronic disease. In terms of stage of development, The firm focuses on early stage technology, which has demonstrated proof of concept and received grant funding.

In the early stages of the company’s development, the firm provides extensive management support including technical guidance, administrative support, legal, IP and commercial expertise. As companies mature through key milestones, the firm will recruit experienced industry leading CEOs to drive the next phase of growth, attract additional external capital and secure favourable exits. The firm seeks to invest in game-changing technologies based on strong science with great commercial potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: